Evidence map›Paper›PMID 36204469›Full record

ArticleFrontiers in bioengineering and biotechnology2022

A smart nanoplatform for enhanced photo-ferrotherapy of hepatocellular carcinoma.

Longguang Tang, Mingjian Ling, Madiha Zahra Syeda, Rui Sun, Minghui He, Qingchun Mu, Xiulong Zhu, Chunming Huang, Liao Cui

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Longguang TangThe People's Hospital of Gaozhou, Guangdong Medical University, Maoming, China.
Mingjian LingSouthern Medical University Shenzhen Stomatology Hospital (Pingshan), Shenzhen, China.
Madiha Zahra SyedaDepartment of Pharmacology and Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of Respiratory Disease of Zhejiang Province, Hangzhou, China.
Rui SunSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, China.
Minghui HeKey Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China.
Qingchun MuThe People's Hospital of Gaozhou, Guangdong Medical University, Maoming, China.
Xiulong ZhuThe People's Hospital of Gaozhou, Guangdong Medical University, Maoming, China.
Chunming HuangThe People's Hospital of Gaozhou, Guangdong Medical University, Maoming, China.
Liao CuiGuangdong Provincial Key Laboratory of Research and Development of Natural Drugs, and School of Pharmacy, Guangdong Medical University, Dongguan, China.
Guangdong Medical College · CNGaozhou People's Hospital · CNGuangdong Pharmaceutical University · CNSecond Affiliated Hospital of Zhejiang University · CNSouthern Medical University · CNSouthern Medical University Shenzhen Hospital · CNWestlake University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Emerging therapies, such as ferroptosis mediated cancer therapy and phototherapy, offer new opportunities for HCC treatment. The combination of multiple treatments is often more effective than monotherapy, but many of the current treatments are prone to serious side effects, resulting in a serious decline in patients' quality of life. Therefore, the combination therapy of tumor

Indexed as

ferrotherapyGSHhepatocellular carcinomananoparticlePTT

Identifiers

PMID36204469
PMCPMC9530464
OpenAlexW4296482391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.